DualityBio’s DB-1310 Granted U.S. FDA Fast Track Designation for HR+/HER2- Breast Cancer

Preliminary Phase 1/2 Clinical Data for DualityBio and BioNTech B7H3-Targeting ADC Candidate DB-1311/BNT324 in Advanced Gynecological Cancers Presented at ESMO ASIA 2025

DualityBio Included in Hong Kong Exchange TECH-100 Index and FTSE Global Equity Index Series Small Cap Constituents